Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14876 - 14900 of 14941 in total

1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)-6-HYDROXYPYRIMIDINE-2,4(1H,3H)-DIONE

Experimental

2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine

Experimental

6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine

Experimental

CRA-9334

Experimental

Doramapimod

Doramapimod is a P38 MAP kinase inhibitor.
Investigational

(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

1-[2-(3-ACETYL-2-HYDROXY-6-METHOXY-PHENYL)-CYCLOPROPYL]-3-(5-CYANO-PYRIDIN-2-YL)-THIOUREA

Experimental

CRA_1802

Experimental

CRA_10972

Experimental

CRA_11092

Experimental

NRP409

NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational

Dapansutrile

Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).
Investigational

Cambinol

Cambinol is a beta-naphtol derivative that inhibits NAD-dependant deacetylases to reduce cell survival under stress. This activity is currently being investigated for its use as a cancer treatment.
Experimental

PH94B

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
Investigational

REN-850

REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Investigational

1,8-Di-Hydroxy-4-Nitro-Anthraquinone

Experimental

AP5346

AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.
Investigational

Terevalefim

Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational

Sarconeos

Sarconeos is an activator of the MAS receptor.
Investigational

1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One

Experimental

RAF-265

Investigational

ALGRX 1207

ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational

AR-AO-14418

Experimental

Tin protoporphyrin IX

Investigational

R-348

Investigational
Displaying drugs 14876 - 14900 of 14941 in total